Information:
Error:
Description:
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Post-Treatment Assessments
Link:
https://clinicaltrials.gov/ct2/show/NCT00373425Keywords:
Versions (3)
- 7/27/16 7/27/16 -
- 8/1/16 8/1/16 -
- 9/27/16 9/27/16 -
Uploaded on:
September 27, 2016
DOI:
To request one please log in.License :
Creative Commons BY 4.0Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.